Compare Cigna Corp (CI) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs DuPont de Nemours Inc — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while DuPont de Nemours Inc trades at $144.26 (market cap $19.12B). The key difference: Cigna Corp is far larger — about 3.8× DuPont de Nemours Inc's market cap, and Cigna Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| CI | DD | |
|---|---|---|
Market Cap | $73.56B | $19.12B |
Sector | Health | Basic Materials |
52-Week High | $311.00 | $154.59 |
52-Week Low | $244.41 | $87.72 |
Enterprise Value | $98.27B | $20.50B |
Dividend Yield | 2.24% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
DuPont (DD) trades at $142.48, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with EPS of $1.88 versus $1.76 expected, and raised its full-year 2026 outlook, driven by healthcare, industrial water, and aerospace demand. However, 2025 fundamentals show a net loss of $779 million on revenue of $6.85 billion, with a high P/E ratio of 61.15 indicating premium valuation.
The outlook is cautiously optimistic, supported by earnings momentum and innovation awards, but risks include ongoing legal settlements over PFAS chemicals and thin net margins. The consensus price target of $232.80 suggests significant upside potential if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
